BioAge Labs, Inc.
BIOA · XNASCIK 1709941fmd_0GWVMMZX0N41S8GRWRM8VWSYFWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2023 to Sep 30, 2026, 15 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Total revenues | – | 0 | 9 |
| Research and development | 34 | 59 | 74 |
| Total operating expenses | 48 | 78 | 102 |
| Operating income | (48) | (78) | (93) |
| Interest expense | 8 | 2 | 1 |
| Interest and investment income | 2 | 10 | 13 |
| Other non-operating income (expense) | (15) | 7 | 12 |
| Income before taxes | (64) | (71) | (81) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (64) | (71) | (81) |
| Net income | (64) | (71) | (81) |